PMID- 31688597
OWN - NLM
STAT- MEDLINE
DCOM- 20200921
LR  - 20201101
IS  - 1536-4828 (Electronic)
IS  - 0885-3177 (Print)
IS  - 0885-3177 (Linking)
VI  - 48
IP  - 10
DP  - 2019 Nov/Dec
TI  - Portal Vein Thrombosis After Total Pancreatectomy and Islet Autotransplant: 
      Prophylaxis and Graft Impact.
PG  - 1329-1333
LID - 10.1097/MPA.0000000000001421 [doi]
AB  - OBJECTIVES: To determine the rate of portal vein thrombosis (PVT) based on 
      pharmacologic prophylaxis protocol and the impact of PVT on islet graft function 
      after total pancreatectomy with islet autotransplantation (TPIAT). METHODS: We 
      compared the incidence of PVT, postsurgical bleeding, and thrombotic 
      complications in patients undergoing TPIAT between 2001 and 2018 at the 
      University of Minnesota who received either unfractionated heparin (UFH) or 
      enoxaparin for postoperative PVT prophylaxis. Six-month and 1-year graft function 
      was compared between patients who developed PVT and those who did not. RESULTS: 
      Twelve patients (6.6%) developed a PVT, which resolved by 6 months after TPIAT in 
      10 patients. There was no statistically significant difference in PVT rate 
      between patients who received UFH or enoxaparin for prophylaxis (P = 0.54). 
      Patients who received enoxaparin developed other thrombotic complications more 
      often (6% vs 0%, P = 0.02). Islet graft function did not differ in patients who 
      developed PVT versus those who did not. CONCLUSIONS: There was no difference 
      between enoxaparin or UFH prophylaxis in preventing PVT, but there may be a 
      higher incidence of other thrombotic complications with enoxaparin. In the 
      setting of routine screening and anticoagulation therapy, PVT is a self-limited 
      process.
FAU - Robbins, Alexandria J
AU  - Robbins AJ
AD  - From the Departments of Surgery.
FAU - Skube, Mariya E
AU  - Skube ME
AD  - From the Departments of Surgery.
FAU - Bellin, Melena D
AU  - Bellin MD
AD  - Medicine.
AD  - Pediatrics, University of Minnesota Medical School, Minneapolis, MN.
FAU - Dunn, Ty B
AU  - Dunn TB
AD  - Department of Surgery, University of Pennsylvania, Philadelphia, PA.
FAU - Chapman, Scott A
AU  - Chapman SA
AD  - Department of Experimental and Clinical Pharmacology, University of Minnesota 
      College of Pharmacy, Minneapolis, MN.
FAU - Berry, K Louise
AU  - Berry KL
AD  - From the Departments of Surgery.
FAU - Lusczek, Elizabeth
AU  - Lusczek E
AD  - From the Departments of Surgery.
FAU - Beilman, Gregory J
AU  - Beilman GJ
AD  - From the Departments of Surgery.
LA  - eng
GR  - T32 DK108733/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - Pancreas
JT  - Pancreas
JID - 8608542
RN  - 0 (Enoxaparin)
RN  - 9005-49-6 (Heparin)
SB  - IM
MH  - Adult
MH  - Enoxaparin/therapeutic use
MH  - Female
MH  - Heparin/therapeutic use
MH  - Humans
MH  - Islets of Langerhans Transplantation/*adverse effects
MH  - Male
MH  - Middle Aged
MH  - Pancreatectomy/*adverse effects
MH  - *Portal Vein
MH  - Postoperative Complications/*prevention & control
MH  - Retrospective Studies
MH  - Transplantation, Autologous
MH  - Venous Thrombosis/*prevention & control
PMC - PMC7181460
MID - NIHMS1539963
COIS- Disclosure: The authors declare no conflict of interest.
EDAT- 2019/11/07 06:00
MHDA- 2020/09/22 06:00
PMCR- 2020/11/01
CRDT- 2019/11/06 06:00
PHST- 2019/11/06 06:00 [entrez]
PHST- 2019/11/07 06:00 [pubmed]
PHST- 2020/09/22 06:00 [medline]
PHST- 2020/11/01 00:00 [pmc-release]
AID - 00006676-201911000-00016 [pii]
AID - 10.1097/MPA.0000000000001421 [doi]
PST - ppublish
SO  - Pancreas. 2019 Nov/Dec;48(10):1329-1333. doi: 10.1097/MPA.0000000000001421.